Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono/ Domain Parkinson's deal

Merck Serono and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's

Merck Serono - Merck's biopharmaceutical division - and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's disease.

The agreement will see France-based biopharmaceutical company, Domain, offer Merck access to a portfolio of optimised investigational compounds. In return, Domain will receive €2m in an upfront payment, with up to €132m available in milestone payments for the first two products to be developed.

The compounds to be developed are positive allosteric modulators for metabotropic glutamate receptor 4 (mGluR4). Glutamate receptors are a member of the G-protein coupled receptor (GPCR) family, a group of proteins which transmit signals into cells, and are seen as therapeutic targets for Parkinson's disease.

"We are pleased to have the opportunity to work with Domain Therapeutics, which has developed great expertise in the GPCR area," said Bernhard Kirschbaum, executive vice president for global research and development at Merck Serono. "This partnership with Domain Therapeutics reflects our long-term commitment to develop new treatments for neurodegenerative diseases."

Pascal Neuville, CEO, Domain Therapeutics, said: "This agreement is a validation of Domain Therapeutics' business model of addressing difficult GPCRs and partnering compounds, with a significant deal, at an early stage of development."

17th January 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....